About
Sabrina advises listed and non-listed clients in stock corporation law and capital markets law, including Corporate Governance, and monitors regularly national and cross-border private and public M&A transactions.
She speaks German, English, Spanish and Armenian.
Additional Information
- Novartis on the public takeover of MorphoSys, the delisting purchase offer and the merger squeeze-out
- BASF on the merger between Wintershall Dea and Harbour Energy
- BorgWarner on the public takeover of Akasol
- TE Connectivity on the public takeover of First Sensor and on the conclusion of a domination and profit and loss pooling agreement with Akasol
- OSRAM Licht on the competing public takeover offers by Bain Capital/Carlyle and ams, the domination and profit and loss pooling agreement with ams and the delisting
- STADA Arzneimittel in the context of the auction process and subsequent public takeover by Bain Capital and Cinven as well as the conclusion of a domination and profit and loss pooling agreement with Bain Capital and Cinven
- London Stock Exchange on the proposed business combination with Deutsche Börse
"very strong, the best of the new generation"
— Competitor, JUVE 2022/23
Dr. Sabrina Kulenkamp
Partner
T +49 69 27 30 80
frankfurt am main Office
Bockenheimer Anlage 44
60322 frankfurt am main